# Amgen (AMGN) financials

Amgen reported revenue of $36.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 10.0% from fiscal 2024. Net income was $7.71 billion and diluted earnings per share $14.23.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $10.4 billion, up 8.5% from a year earlier.

Source: Amgen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/AMGN. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Amgen reported revenue of $10.4 billion, up 8.5% from a year earlier, net income of $3.86 billion and diluted earnings per share of $7.08 against $5.93 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 3 Nov 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $10.37B | $9.56B | +8.5% |
| Gross profit | $7.58B | $6.47B | +17.0% |
| Gross margin | 73.1% | 67.8% | +5.4 pts |
| Operating income | $3.71B | $2.53B | +46.9% |
| Operating margin | 35.8% | 26.4% | +9.4 pts |
| Net income | $3.86B | $3.22B | +20.1% |
| Diluted EPS | $7.08 | $5.93 | +19.4% |
| Operating cash flow | $4.24B | $4.68B | −9.5% |
| Capital expenditure | $587.0M | $436.0M | +34.6% |
| Free cash flow | $3.65B | $4.25B | −14.0% |

Page: https://aapwire.com/stocks/AMGN/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| Revenue growth | +6.1% | −0.6% | +3.9% | −1.6% | +8.8% | +2.2% | +1.3% | +7.1% | +18.6% | +10.0% |
| Gross profit | $18.83B | $18.78B | $19.65B | $19.01B | $19.27B | $19.52B | $19.92B | $19.74B | $20.57B | $24.71B |
| Operating income | $9.79B | $9.97B | $10.26B | $9.67B | $9.14B | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B |
| Net income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B |
| Diluted EPS | $10.24 | $2.69 | $12.62 | $12.88 | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Operating cash flow | $10.35B | $11.18B | $11.30B | $9.15B | $10.50B | $9.26B | $9.72B | $8.47B | $11.49B | $9.96B |
| Capital expenditure | $738.0M | $664.0M | $738.0M | $618.0M | $608.0M | $880.0M | $936.0M | $1.11B | $1.10B | $1.86B |
| Free cash flow | $9.62B | $10.51B | $10.56B | $8.53B | $9.89B | $8.38B | $8.79B | $7.36B | $10.39B | $8.10B |
| Gross margin | 81.9% | 82.2% | 82.7% | 81.4% | 75.8% | 75.2% | 75.7% | 70.0% | 61.5% | 67.2% |
| Operating margin | 42.6% | 43.6% | 43.2% | 41.4% | 35.9% | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% |
| Net margin | 33.6% | 8.7% | 35.3% | 33.6% | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| Cash and equivalents | $3.24B | $3.80B | $6.95B | $6.04B | $6.27B | $7.99B | $7.63B | $10.94B | $11.97B | $9.13B |
| Total debt | $34.60B | $35.34B | $33.93B | $30.43B | $33.45B | $33.98B | $39.64B | $65.42B | $60.88B | $55.44B |
| Shareholders' equity | $29.88B | $25.24B | $12.50B | $9.67B | $9.41B | $6.70B | $3.66B | $6.23B | $5.88B | $8.66B |
| Diluted shares | 754M | 735M | 665M | 609M | 590M | 573M | 541M | 538M | 541M | 542M |
| Dividends per share | $4.15 | $4.77 | $5.41 | $5.95 | $6.56 | $7.22 | $7.95 | $8.64 | $9.13 | $9.66 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B | $10.05B | $10.37B |
| Revenue, year on year | +10.9% | +9.4% | +9.4% | +12.4% | +8.6% | +5.8% | +9.5% | +8.5% |
| Gross margin | 65.7% | 63.6% | 67.2% | 67.8% | 69.8% | 68.2% | 72.0% | 73.1% |
| Operating income | $2.31B | $1.18B | $2.66B | $2.53B | $2.72B | $2.67B | $3.51B | $3.71B |
| Net income | $627.0M | $1.73B | $1.43B | $3.22B | $1.33B | $1.82B | $2.38B | $3.86B |
| Diluted EPS | $1.16 | $3.20 | $2.65 | $5.93 | $2.46 | $3.34 | $4.37 | $7.08 |
| Free cash flow | $4.40B | $980.0M | $1.91B | $4.25B | $961.0M | $1.48B | $3.49B | $3.65B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Product sales](https://aapwire.com/stocks/AMGN/kpi/product-sales) | $9.9B | quarter to 30 Sep 2026 | up 8.2% |
| [Repatha revenue](https://aapwire.com/stocks/AMGN/kpi/repatha-revenue) | $1.1B | quarter to 30 Sep 2026 | up 36.6% |
| [EVENITY revenue](https://aapwire.com/stocks/AMGN/kpi/evenity-revenue) | $751.0M | quarter to 30 Sep 2026 | up 38.8% |
| [Prolia revenue](https://aapwire.com/stocks/AMGN/kpi/prolia-revenue) | $632.0M | quarter to 30 Sep 2026 | down 44.5% |
| [ENBREL revenue](https://aapwire.com/stocks/AMGN/kpi/enbrel-revenue) | $611.0M | quarter to 30 Sep 2026 | up 5.3% |
| [TEZSPIRE revenue](https://aapwire.com/stocks/AMGN/kpi/tezspire-revenue) | $538.0M | quarter to 30 Sep 2026 | up 42.7% |
| [TEPEZZA revenue](https://aapwire.com/stocks/AMGN/kpi/tepezza-revenue) | $526.0M | quarter to 30 Sep 2026 | down 6.1% |
| [BLINCYTO revenue](https://aapwire.com/stocks/AMGN/kpi/blincyto-revenue) | $496.0M | quarter to 30 Sep 2026 | up 26.5% |
| [Otezla revenue](https://aapwire.com/stocks/AMGN/kpi/otezla-revenue) | $481.0M | quarter to 30 Sep 2026 | down 17.8% |
| [Nplate revenue](https://aapwire.com/stocks/AMGN/kpi/nplate-revenue) | $472.0M | quarter to 30 Sep 2026 | up 3.3% |
| [UPLIZNA revenue](https://aapwire.com/stocks/AMGN/kpi/uplizna-revenue) | $451.0M | quarter to 30 Sep 2026 | up 191.0% |
| [KRYSTEXXA revenue](https://aapwire.com/stocks/AMGN/kpi/krystexxa-revenue) | $419.0M | quarter to 30 Sep 2026 | up 30.9% |
| [IMDELLTRA/IMDYLLTRA revenue](https://aapwire.com/stocks/AMGN/kpi/imdelltra-imdylltra-revenue) | $406.0M | quarter to 30 Sep 2026 | up 128.1% |
| [Vectibix revenue](https://aapwire.com/stocks/AMGN/kpi/vectibix-revenue) | $335.0M | quarter to 30 Sep 2026 | up 18.0% |
| [KYPROLIS revenue](https://aapwire.com/stocks/AMGN/kpi/kyprolis-revenue) | $330.0M | quarter to 30 Sep 2026 | down 8.1% |
| [Aranesp revenue](https://aapwire.com/stocks/AMGN/kpi/aranesp-revenue) | $329.0M | quarter to 30 Sep 2026 | down 7.8% |
| [XGEVA revenue](https://aapwire.com/stocks/AMGN/kpi/xgeva-revenue) | $288.0M | quarter to 30 Sep 2026 | down 46.6% |
| [United States revenue](https://aapwire.com/stocks/AMGN/kpi/united-states-revenue) | $26.4B | fiscal year to 31 Dec 2025 | up 10.7% |
| [ROW revenue](https://aapwire.com/stocks/AMGN/kpi/row-revenue) | $10.3B | fiscal year to 31 Dec 2025 | up 8.1% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
